2C-B: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Repoint receptor links to the new Receptor: namespace |
MDElliottMD (talk | contribs) Link legal-status field to the USLegal: namespace |
||
| Line 15: | Line 15: | ||
| bioavailability = Not well characterized | | bioavailability = Not well characterized | ||
| pregnancy = Not established | | pregnancy = Not established | ||
| legal = Schedule I (United States) | | legal = [[USLegal:DEA Schedule I|Schedule I]] (United States) | ||
| mechanism = 5-HT2A partial agonist | | mechanism = 5-HT2A partial agonist | ||
| intro = 2C-B, chemically 4-bromo-2,5-dimethoxyphenethylamine, is a synthetic psychedelic [[:Category:Phenethylamines|phenethylamine]] first prepared in 1974 by [[Alexander Shulgin]] at his home laboratory in Lafayette, California. It is the founding member of the [[:Category:2C-x series|2C series]], a family of 2,5-dimethoxy-4-substituted phenethylamines that Shulgin and his collaborators developed as variations on the [[Mescaline|mescaline]] skeleton. 2C-B occupies a distinctive position in the psychedelic medicine landscape: a compound with a mescaline-class structural lineage, a [[Receptor:5-HT2A|5-HT2A]] pharmacology shared with the [[:Category:Psychedelics|classical psychedelics]], and a subjective character that has been described as bridging the [[:Category:Empathogens|entactogenic]] register of [[MDMA]] and the visionary register of the classical psychedelics. It had a brief legal-sale era in the late 1980s and early 1990s before being placed in [[Schedule I]] of the United States [[Controlled Substances Act]], temporarily in 1994 and permanently in 1995, and in Schedule II of the [[Convention on Psychotropic Substances|United Nations Convention on Psychotropic Substances]] in 2001. | | intro = 2C-B, chemically 4-bromo-2,5-dimethoxyphenethylamine, is a synthetic psychedelic [[:Category:Phenethylamines|phenethylamine]] first prepared in 1974 by [[Alexander Shulgin]] at his home laboratory in Lafayette, California. It is the founding member of the [[:Category:2C-x series|2C series]], a family of 2,5-dimethoxy-4-substituted phenethylamines that Shulgin and his collaborators developed as variations on the [[Mescaline|mescaline]] skeleton. 2C-B occupies a distinctive position in the psychedelic medicine landscape: a compound with a mescaline-class structural lineage, a [[Receptor:5-HT2A|5-HT2A]] pharmacology shared with the [[:Category:Psychedelics|classical psychedelics]], and a subjective character that has been described as bridging the [[:Category:Empathogens|entactogenic]] register of [[MDMA]] and the visionary register of the classical psychedelics. It had a brief legal-sale era in the late 1980s and early 1990s before being placed in [[Schedule I]] of the United States [[Controlled Substances Act]], temporarily in 1994 and permanently in 1995, and in Schedule II of the [[Convention on Psychotropic Substances|United Nations Convention on Psychotropic Substances]] in 2001. | ||